Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI...
COVID-19
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential...
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update
Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand...
UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions
SHENZHEN, China, Aug. 19, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce a...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company...
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.
SALT LAKE CITY, Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a...
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected...
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
NHI Announces Pricing of Upsized Public Offering of Common Stock
MURFREESBORO, TN / ACCESSWIRE / August 14, 2024 / National Health Investors, Inc. (NYSE:NHI) (the "Company") announced today the pricing...
Acreage Reports Second Quarter 2024 Financial Results
Commenced Non-Medical Sales in Ohio Market, Expected to Double Revenue in the State by 2025 from ~$50 million in 2023Focused...
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica"...
NHI Announces Public Offering Of Common Stock
MURFREESBORO, TN / ACCESSWIRE / August 14, 2024 / National Health Investors, Inc. (NYSE:NHI) (the "Company") announced today that it...
Spero Clinic Offers Hope for Long COVID Patients
Unique treatment program offers promising results for Long COVID patients who are experiencing extreme symptoms related to the virus.FAYETTEVILLE, AR...
Moderna and Coursera Launch Free Course on mRNA Technology
Companies share joint commitment to leveraging technology for STEM educationAccessible education on cutting-edge science and technology represents critical step toward...
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE /...
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenueNotable acceleration of commercial results in early Q3...
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine)...